EKI 785
Latest Information Update: 26 Oct 2005
At a glance
- Originator Wyeth
- Class
- Mechanism of Action Epidermal growth factor inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Autosomal recessive polycystic kidney disease
Most Recent Events
- 26 Oct 2005 Discontinued - Preclinical for Autosomal recessive polycystic kidney disease in USA (unspecified route)
- 25 Mar 2002 American Home Products and its subsidiaries Wyeth-Ayerst and Wyeth Lederle are both now called Wyeth
- 29 Feb 2000 A preclinical study has been added to the pharmacodynamics and adverse events sections